FDA Panel To Assess Excessive Sedation Linked To Lilly’s Zyprexa Depot Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Psychopharmacologic Drugs Advisory Committee will vote Feb. 6 on the safety and efficacy of the long-acting atypical antipsychotic.